União Europeia - português - EMA (European Medicines Agency)

viatris limited - pirfenidone - idiopathic pulmonary fibrosis; lung diseases; respiratory tract diseases - imunossupressores - pirfenidone viatris is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (ipf).

União Europeia - português - EMA (European Medicines Agency)

viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - drogas usadas em diabetes - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 e 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.

União Europeia - português - EMA (European Medicines Agency)

viatris limited - clopidogrel besilate - peripheral vascular diseases; stroke; myocardial infarction - agentes antitrombóticos - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). segmento st elevação infarto agudo do miocárdio, em combinação com asa em medicamente tratados os pacientes elegíveis para terapia trombolítica. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. para mais informações, por favor consulte a secção 5.

União Europeia - português - EMA (European Medicines Agency)

merck sharp & dohme b.v. - raltegravir - infecções por hiv - antivirais para uso sistêmico - isentress é indicado em combinação com outros medicamentos anti-retrovirais para o tratamento do vírus da imunodeficiência humana (hiv 1) infecção.

União Europeia - português - EMA (European Medicines Agency)

novartis europharm limited - sacubitril, valsartan - insuficiência cardíaca - a angiotensina ii, os antagonistas, outras combinações, os agentes que actuam no sistema renina-angiotensina - paediatric heart failureentresto is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction. adult heart failureentresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

novartis biociencias s.a - sacubitril valsartana sÓdica hidratada - agentes que atuam no sistema renina-angiotensina

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

merck sharp & dohme farmaceutica ltda. - raltegravir potássico - antiviroticos

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

bial - portela & cª, s.a. - bupropiom - comprimido de libertação modificada - 300 mg - bupropiom, cloridrato 300 mg - other antidepressants - n/a - duração do tratamento: longa duração

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

bial - portela & cª, s.a. - bupropiom - comprimido de libertação modificada - 300 mg - bupropiom, cloridrato 300 mg - other antidepressants - n/a - duração do tratamento: longa duração

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

bial - portela & cª, s.a. - bupropiom - comprimido de libertação modificada - 150 mg - bupropiom, cloridrato 150 mg - other antidepressants - n/a - duração do tratamento: longa duração